Immune checkpoint inhibitors that can target CTLA-4 and the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis induce significantly enhanced therapeutic responses in cancer immunotherapy [70,71]. Here, CTLA4 is linked to cancer.